Zacks: Mesa Laboratories, Inc. (MLAB) Receives Average Rating of “Strong Buy” from Brokerages

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $255.00 for the company and are forecasting that the company will post $2.13 EPS for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 67 out of 255 based on the ratings given to its competitors.

Several equities analysts have weighed in on the company. Zacks Investment Research upgraded Mesa Laboratories from a “hold” rating to a “buy” rating and set a $257.00 target price on the stock in a report on Friday. ValuEngine raised Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, October 23rd. Finally, BidaskClub raised Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, October 26th.



Shares of NASDAQ:MLAB opened at $230.90 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.57 and a debt-to-equity ratio of 0.25. Mesa Laboratories has a 1 year low of $124.29 and a 1 year high of $239.08. The firm has a market cap of $906.50 million, a P/E ratio of 37.36 and a beta of 0.41.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 15th. Shareholders of record on Thursday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Wednesday, February 27th. Mesa Laboratories’s payout ratio is 10.36%.

In other news, Director Seg Ventures, Llc purchased 20,000 shares of the firm’s stock in a transaction dated Sunday, December 30th. The stock was bought at an average price of $23.10 per share, with a total value of $462,000.00. Following the acquisition, the director now directly owns 120,000 shares of the company’s stock, valued at $2,772,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David M. Kelly sold 1,700 shares of the company’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $210.94, for a total transaction of $358,598.00. Following the completion of the transaction, the director now directly owns 3,600 shares of the company’s stock, valued at $759,384. The disclosure for this sale can be found here. Insiders have sold a total of 23,200 shares of company stock valued at $5,027,868 in the last quarter. Corporate insiders own 15.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its holdings in shares of Mesa Laboratories by 2.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 486,256 shares of the medical instruments supplier’s stock valued at $101,331,000 after purchasing an additional 10,817 shares during the period. BlackRock Inc. raised its holdings in Mesa Laboratories by 10.2% in the 4th quarter. BlackRock Inc. now owns 252,580 shares of the medical instruments supplier’s stock valued at $52,634,000 after acquiring an additional 23,384 shares during the period. Vanguard Group Inc. raised its holdings in Mesa Laboratories by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 161,627 shares of the medical instruments supplier’s stock valued at $30,000,000 after acquiring an additional 3,309 shares during the period. Vanguard Group Inc raised its holdings in Mesa Laboratories by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 161,627 shares of the medical instruments supplier’s stock valued at $30,000,000 after acquiring an additional 3,309 shares during the period. Finally, Kayne Anderson Rudnick Investment Management LLC raised its holdings in Mesa Laboratories by 1.4% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 155,388 shares of the medical instruments supplier’s stock valued at $32,382,000 after acquiring an additional 2,220 shares during the period. 70.31% of the stock is owned by hedge funds and other institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Recommended Story: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply